CN116474011A - Preparation method and application of ginseng stem and leaf extract oral liquid - Google Patents
Preparation method and application of ginseng stem and leaf extract oral liquid Download PDFInfo
- Publication number
- CN116474011A CN116474011A CN202310451296.8A CN202310451296A CN116474011A CN 116474011 A CN116474011 A CN 116474011A CN 202310451296 A CN202310451296 A CN 202310451296A CN 116474011 A CN116474011 A CN 116474011A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- ginseng stem
- leaf extract
- solution
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 60
- 241000208340 Araliaceae Species 0.000 title claims abstract description 49
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 49
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 49
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 49
- 239000000284 extract Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 238000002791 soaking Methods 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 229960005486 vaccine Drugs 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 230000001900 immune effect Effects 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000006184 cosolvent Substances 0.000 claims abstract description 8
- 238000002255 vaccination Methods 0.000 claims abstract description 8
- 238000004806 packaging method and process Methods 0.000 claims abstract description 6
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 230000001105 regulatory effect Effects 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 9
- 244000144972 livestock Species 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 229930182490 saponin Natural products 0.000 claims description 7
- 150000007949 saponins Chemical class 0.000 claims description 7
- 235000017709 saponins Nutrition 0.000 claims description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical group [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims description 7
- 239000004299 sodium benzoate Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 12
- 206010062016 Immunosuppression Diseases 0.000 abstract description 10
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 10
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 abstract description 9
- 238000000605 extraction Methods 0.000 abstract description 5
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract description 4
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 3
- 238000002386 leaching Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 10
- 230000036737 immune function Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000002649 immunization Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241001673669 Porcine circovirus 2 Species 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A preparation method and application of ginseng stem and leaf extract oral liquid relate to the technical field of ginseng stem and leaf extract preparation, the adopted technical scheme comprises S1, cutting raw materials into segments, weighing a certain amount, and soaking with 8-12 times of ethanol solution; s2, collecting ethanol soaking liquid, filtering and decompressing to recover ethanol; s3, adding a cosolvent and a preservative, adding purified water and uniformly stirring; s4, regulating the pH value, filtering, encapsulating and packaging. The invention adopts ginseng stem and leaf as raw material, has low cost, adopts an alcohol leaching extraction method, has little damage loss to the effective components ginsenoside Rg1 (C42H 72O 14) and Re (C48H 82O 18), and has high content of the effective components in the oral liquid; the oral liquid can effectively activate the immune system of the organism after being drunk by animals before vaccination, and the organism can rapidly generate immune response after vaccination, thereby solving the problem of poor immune effect of the vaccine caused by animal immune hypofunction and immunosuppression.
Description
Technical Field
The invention relates to the technical field of preparation of ginseng stem and leaf extracts, in particular to a preparation method and application of ginseng stem and leaf extract oral liquid.
Background
The method for preventing and controlling animal epidemic diseases is one of effective means, and the quality of the immunization effect depends on external factors such as the dosage of the vaccine, the inoculation route, the immunization program and the like during the inoculation, and also depends on the self health condition of animal organisms. Among them, the immune function of animals is lowered and immunosuppression caused by various reasons may adversely affect the immune effect of vaccines. The reasons include reduced immune function due to stress factors such as weather changes, excessive feeding density, poor ventilation, population transfer and transportation, immunosuppression due to abuse of drugs, nutritional immunosuppression due to deficiency of vitamins and proteins, etc. Thus, although animals are immunized, sometimes a desired immune effect cannot be produced, and it is necessary to solve the problems of low immune function and immunosuppression of animals to improve the immune effect of vaccines.
Disclosure of Invention
Aiming at the problem of unsatisfactory vaccine immune effect caused by low autoimmune function and immunosuppression of animals in the prior art scheme, the invention provides a preparation method and application of ginseng stem and leaf extract oral liquid.
The invention provides the following technical scheme: a preparation method of ginseng stem and leaf extract oral liquid comprises the following steps:
s1, cutting the raw materials into segments, weighing a certain amount, and soaking the segments in an ethanol solution with an amount of 8-12 times that of the raw materials;
s2, collecting ethanol soaking liquid, filtering and decompressing to recover ethanol;
s3, adding a cosolvent and a preservative, adding purified water and uniformly stirring;
s4, regulating the pH value, filtering, encapsulating and packaging to obtain the oral liquid;
in step S1, the raw materials are ginseng stems and/or leaves, and in step S4, the active ingredients of the oral liquid consist of ginseng stem and leaf saponins Rg1 (C42H 72O 14) and Re (C48H 82O 18).
Preferably, the mass of the raw materials required for preparing 1000 mL oral liquid is 1800-2200 g.
Preferably, in the step S1, the length of the cut section of the raw material is 1.5-2.5 cm.
Preferably, in step S1, the concentration of the ethanol solvent is 60% vol.
Preferably, in step S2, the temperature recovered under reduced pressure is 55 ℃.
Preferably, in step S3, the cosolvent is tween-80 solution and the preservative is sodium benzoate solution.
Preferably, the addition amount of the tween-80 solution and the sodium benzoate solution is 0.5 percent of the volume of the solution after the decompression recovery.
Preferably, in step S4, the pH value of the oral liquid is 4.5-5.5.
An application of ginseng stem and leaf extract oral liquid in improving livestock vaccine immunity is provided.
Preferably, the oral liquid is administered to livestock after adding water 3 days prior to vaccination.
The beneficial effects of the invention are as follows: the ginseng stem and leaf is used as a raw material, the cost is low, the damage loss to the ginsenoside Rg1 (C42H 72O 14) and Re (C48H 82O 18) which are active ingredients in the ginseng stem and leaf is small, and the content of the active ingredients in the oral liquid is high; the oral liquid can effectively activate the immune system of the organism after being drunk by animals before vaccination, and the organism can quickly generate immune response reaction after vaccination to generate antibodies, and the antibody titer is high, the antibodies are regular and the protection rate is high, so as to solve the problem of poor immune effect of the vaccine caused by animal immune function low and immune suppression.
Drawings
FIG. 1 is a graph of IgG antibody response following immunization with PCV2 vaccine.
Description of the embodiments
Embodiments of the present invention will be described in more detail below with reference to the drawings and reference numerals, so that those skilled in the art can practice the present invention after studying the specification. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
The invention provides a preparation method of ginseng stem and leaf extract oral liquid, which comprises the following steps.
S1, cutting stems and leaves of ginseng into small sections with the length of 1.5 and cm, weighing 1800 and g, putting into a multifunctional extraction pot, soaking with 8 times of 60% vol ethanol solution, and standing for 24 h. The 8 times amount refers to the feed liquid ratio of ginseng stem and leaf to ethanol solution of 1:8 (g/mL).
S2, collecting ethanol soaking liquid, filtering to remove impurities, recovering ethanol under reduced pressure at 55 ℃, and concentrating the soaking liquid to 900 mL.
S3, adding Tween-80 solution as a cosolvent and sodium benzoate solution as a preservative into the soaking solution, wherein the addition amount of the preservative is 0.5% of the volume of the soaking solution; then, purified water was added to raise the volume of the immersion liquid to 1000 mL, and the immersion liquid was stirred uniformly.
S4, adjusting the pH value of the soaking solution to 4.5-5.5, filtering, encapsulating and packaging to obtain the ginseng stem and leaf extract oral liquid.
Example 2
The invention provides a preparation method of ginseng stem and leaf extract oral liquid, which comprises the following steps.
S1, cutting stems and leaves of ginseng into small sections with the length of 2 cm, weighing 2000 g, putting into a multifunctional extraction pot, soaking in 10 times of 60% Vol ethanol solution, and standing for 24 h. The 10 times of the weight of the ginseng is that the feed liquid ratio of ginseng stems and leaves to the ethanol solution is 1:10.
S2, collecting ethanol soaking liquid, filtering to remove impurities, recovering ethanol under reduced pressure at 55 ℃, and concentrating the soaking liquid to 900 mL.
S3, adding Tween-80 solution as a cosolvent and sodium benzoate solution as a preservative into the soaking solution, wherein the addition amount of the preservative is 0.5% of the volume of the soaking solution; then, purified water was added to raise the volume of the immersion liquid to 1000 mL, and the immersion liquid was stirred uniformly.
S4, adjusting the pH value of the soaking solution to 4.5-5.5, filtering, encapsulating and packaging to obtain the ginseng stem and leaf extract oral liquid.
Example 3
The invention provides a preparation method of ginseng stem and leaf extract oral liquid, which comprises the following steps.
S1, cutting stems and leaves of ginseng into small sections with the length of 2.5 and cm, weighing 2200 and g, putting into a multifunctional extraction pot, soaking with 12 times of 60% vol ethanol solution, and standing for 24 h. The 12 times of the weight of the ginseng stem and leaf is that the feed liquid ratio of the ginseng stem and leaf to the ethanol solution is 1:12.
S2, collecting ethanol soaking liquid, filtering to remove impurities, recovering ethanol under reduced pressure at 55 ℃, and concentrating the soaking liquid to 900 mL.
S3, adding Tween-80 solution as a cosolvent and sodium benzoate solution as a preservative into the soaking solution, wherein the addition amount of the preservative is 0.5% of the volume of the soaking solution; then, purified water was added to raise the volume of the immersion liquid to 1000 mL, and the immersion liquid was stirred uniformly.
S4, adjusting the pH value of the soaking solution to 4.5-5.5, filtering, encapsulating and packaging to obtain the ginseng stem and leaf extract oral liquid.
Example 4
An application of ginseng stem and leaf extract oral liquid in improving livestock vaccine immunity is provided. Specifically, the oral liquid is added with water to drink for 3 days before the livestock is vaccinated, so that the immune system of the organism can be effectively activated, the organism can rapidly generate immune response after the vaccination to generate antibodies, and the antibodies have high titer, are neat and have high protection rate.
In the invention, ginseng stems and leaves are used as raw materials, the cost is low, the effective components of the ginseng stems and leaves are composed of ginsenoside Rg1 (C42H 72O 14) and Re (C48H 82O 18), and the damage loss of the effective components is small by adopting an alcohol leaching extraction method. The ginsenoside Rg1 (C42H 72O 14) and Re (C48H 82O 18) can effectively activate the immune system of organism, and has regulating effect on immune organ, immune tissue and immune cells.
Immune organs are divided into central immune organs, which consist of thymus and bone marrow, and peripheral immune organs, which consist mainly of spleen, lymph nodes, etc. By establishing a cyclophosphamide-induced mouse model with low immune function, the influence of ginseng stem and leaf saponin Rg1 (C42H 72O 14) and Re (C48H 82O 18) on thymus index and spleen index of mice is researched, and as a result, the results show that the thymus index and the spleen index of the mice with low immune function are obviously lower than those of normal mice, the thymus index and the spleen index of the mice can be obviously improved by the ginseng stem and leaf saponin Rg1 (C42H 72O 14) and Re (C48H 82O 18), and the immune defense capacity of organisms is improved by improving the thymus index and the spleen index by the ginseng stem and leaf saponin Rg1 (C42H 72O 14) and Re (C48H 82O 18).
The ginseng stem leaf saponin increases the transcription of DC secretion IL-12P40 protein and mPNA thereof by promoting the migration and development and maturation of DC precursor cells, increases the phagocytic capacity of IL-2 and phytohemagglutinin to activate macrophages, and simultaneously promotes the release of Nitric Oxide (NO), and the level of NO is also an important index of macrophage activation, so that the regulation effect of ginseng stem leaf saponin Rg1 (C42H 72O 14) and Re (C48H 82O 18) on specific immune functions and nonspecific immune functions is realized by enhancing the functions of macrophages.
T lymphocytes are important immune cells, which mediate cellular immunity primarily, and B lymphocytes mediate fluid immunity primarily. When both are stimulated by antigen, they activate, proliferate, differentiate into effector cells, which produce a range of biological effects that mediate an adaptive immune response. And the ginsenoside can obviously enhance the immunocompetence of T, B lymphocytes.
To study the effect of ginseng stem and leaf extract oral liquid on the immune effect of animals vaccinated under immunosuppression, 60 mice were randomly divided into 6 groups of 10 mice each, an immunosuppression model was established for A, B, C, D groups, and E, F groups were healthy mice. The method for establishing the immunosuppression model is to establish a mouse scalding model and inject endotoxin into the abdominal cavity of the mouse for secondary striking, so that the immune function of the mouse is reduced.
The oral liquid prepared in example 2 was fed to A, C groups with drinking water, the addition amount of the oral liquid was 0.1mL, 1 time a day for 3 consecutive days, and B, D, E, F groups were fed with no drinking water. Mice in group A, B, E were immunized with porcine circovirus type 2 (PCV 2) vaccine on day 4 of the test, C, D, F mice were immunized with foot-and-mouth disease (FMD) vaccine, blood was collected on days 0, 7, 14, 21 after immunization, and the corresponding serum IgG was detected by ELISA detection method, and the results are shown in Table 1, FIG. 1.
Table 1: indirect ELISA assay results
As can be seen from Table 1, the increase in the A, C group antibody was significantly increased for the different vaccines, and A, C group serum D was used for immunization against 14D and 21D 450nm Significantly higher than the B, D group and also higher than the E, F group in which healthy mice are located. It can be seen that the product of the invention has a positive effect on enhancing the immune effect of animals after vaccination under immunosuppression.
The foregoing is a description of one or more embodiments of the invention, which are specific and detailed, but are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.
Claims (10)
1. A preparation method of ginseng stem and leaf extract oral liquid is characterized in that: comprises the steps of,
s1, cutting the raw materials into segments, weighing a certain amount, and soaking the segments in an ethanol solution with an amount of 8-12 times that of the raw materials;
s2, collecting ethanol soaking liquid, filtering and decompressing to recover ethanol;
s3, adding a cosolvent and a preservative, adding purified water and uniformly stirring;
s4, regulating the pH value, filtering, encapsulating and packaging to obtain the oral liquid;
in step S1, the raw materials are ginseng stems and/or leaves, and in step S4, the active ingredients of the oral liquid consist of ginseng stem and leaf saponins Rg1 (C42H 72O 14) and Re (C48H 82O 18).
2. The method for preparing ginseng stem and leaf extract oral liquid according to claim 1, wherein: the mass of the raw materials required for preparing 1000 mL oral liquid is 1800-2200 g.
3. The method for preparing ginseng stem and leaf extract oral liquid according to claim 1, wherein: in the step S1, the length of the cut section of the raw material is 1.5-2.5 cm.
4. The method for preparing ginseng stem and leaf extract oral liquid according to claim 1, wherein: in step S1, the concentration of the ethanol solvent is 60% Vol.
5. The method for preparing ginseng stem and leaf extract oral liquid according to claim 1, wherein: in step S2, the temperature recovered under reduced pressure was 55 ℃.
6. The method for preparing ginseng stem and leaf extract oral liquid according to claim 1, wherein: in step S3, the cosolvent is tween-80 solution, and the preservative is sodium benzoate solution.
7. The method for preparing ginseng stem and leaf extract oral liquid according to claim 5, wherein: the addition amount of the Tween-80 solution and the sodium benzoate solution is 0.5 percent of the volume of the solution after decompression recovery.
8. The method for preparing ginseng stem and leaf extract oral liquid according to claim 5, wherein: in the step S4, the pH value of the oral liquid is 4.5-5.5.
9. Use of the ginseng stem and leaf extract oral liquid according to any one of claims 1 to 8 for improving the immune effect of livestock vaccine.
10. The use of an oral liquid of ginseng stem and leaf extract in improving the immune effect of livestock vaccine according to claim 9, wherein: the oral liquid was administered to livestock after adding water 3 days prior to vaccination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310451296.8A CN116474011A (en) | 2023-04-25 | 2023-04-25 | Preparation method and application of ginseng stem and leaf extract oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310451296.8A CN116474011A (en) | 2023-04-25 | 2023-04-25 | Preparation method and application of ginseng stem and leaf extract oral liquid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116474011A true CN116474011A (en) | 2023-07-25 |
Family
ID=87226433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310451296.8A Pending CN116474011A (en) | 2023-04-25 | 2023-04-25 | Preparation method and application of ginseng stem and leaf extract oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116474011A (en) |
-
2023
- 2023-04-25 CN CN202310451296.8A patent/CN116474011A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9006401B2 (en) | Methods of treatment using thymus-derived compositions | |
| CN103262943A (en) | Lophatherum gracile extract and application thereof | |
| JPWO2016204120A1 (en) | Bamboo fermentation extract production method and immunostimulant | |
| CN108117583A (en) | A kind of immunopotentiator and its application | |
| KR100475406B1 (en) | Composition for Stimulating Immune Response Containing Poly-gamma-glutamic acid | |
| US20050196479A1 (en) | Polysaccharide extract of dioscorea sp. and an orally active pharmaceutical composition comprising the same | |
| CN116474011A (en) | Preparation method and application of ginseng stem and leaf extract oral liquid | |
| CN105477225B (en) | Traditional Chinese veterinary medicine for enhancing anti-stress capability of chicks, preparation method and feeding method | |
| CN104117072B (en) | Multivalent adenovirus vaccine for preventing toxoplasmosis | |
| WO2002098437A1 (en) | Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof | |
| CN113121681B (en) | Anti-inflammatory porcine epidemic diarrhea virus resistant egg yolk antibody and application thereof | |
| JP4860109B2 (en) | Composition for enhancing immunity comprising polygamma glutamic acid | |
| CN105497885B (en) | A kind of subunit vaccine and its preparation method and application | |
| CN104162159A (en) | Composition for resisting canine parvovirus, freeze-dried powder, and preparation method and use of freeze-dried powder | |
| RU2494749C1 (en) | Method of preventing respiratory diseases in calves | |
| WO2005070458A1 (en) | Improved iga production method | |
| CN108727505B (en) | Immune protection combined protein and immune vaccine thereof | |
| Jafari et al. | Study on immunomodulatory activity of dietary garlic in chickens vaccinated against avian influenza virus (subtype H9N2) | |
| CN1382735A (en) | Somatostatin yolk antibody and its preparing process | |
| CN105153292B (en) | A kind of Infection of Toxoplasma Gondii GRA10 multi-epitopes peptide and its vaccine of preparation | |
| CN105362326A (en) | Method for extracting natural active substance from non-heading Chinese cabbages and application thereof | |
| KR101895024B1 (en) | Composition for Enhancement of Immunity | |
| CN104208682A (en) | Composition for preventing chicken Newcastle disease and chicken bursal disease, mixed freeze-dried powder and preparation method | |
| US11471529B2 (en) | Immunopotentiator, foot-and-mouth disease inactivated vaccine and preparation method thereof | |
| CN107158373B (en) | Application of pleurotus ferulae polysaccharide in preparation of dog zona pellucida 3DNA vaccine adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |